DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Vascular Embolization Procedures — Coverage Criteria

Defines medical necessity, prior authorization expectations, and coverage stance for vascular embolization procedures across multiple indications for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyVascular Embolization Procedures — Coverage Criteria

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective Date02 | 01 2026

Next Review DateN/A

Key ActionObtain prior authorization via the web-based tool (required for Medicare Advantage; recommended for Commercial products) and document indication and supporting clinical details.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

16+distinct indications

PA requiredMedicare Advantage

PA recommendedCommercial

Multiplenot covered indications

>6 cmrAML size threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

70-80%PVE → resection success

Coverage Criteria for Vascular Embolization

Medically necessary indications

Covered when the specific indication below is met and any procedure-specific criteria are satisfied

Medically necessary indications: Coil embolization for arterio-venous malformations (AVMs), aneurysm, congenital aorto-azygous fistula, and splenic artery aneurysm; coil embolization of gastric varices; embolization (coil, microsphere, glue, or other agents) for renal angiomyolipoma (AML) if there is active bleeding or AML size greater than 6 cm; transcatheter arterial embolization for non-variceal upper gastrointestinal bleeding; transcatheter embolization for intractable or recurrent severe posterior epistaxis after failed conservative measures; transcatheter embolization for lower gastrointestinal bleeding when the lower GI tract has been identified as the source and ANY of the following are met: (1) colonoscopy localized the bleeding site and endoscopic treatment was attempted; (2) hemodynamically unstable with active lower GIB or transfusion requirement >4 units within 24 hours; (3) hemodynamically stable with obscure recurrent lower GIB after adequate negative colonoscopy and upper endoscopy; endovascular embolization for extracranial AVM or fistula; portal vein embolization before surgical resection of cholangiocarcinoma when marginal future liver remnant precludes resection; geniculate artery embolization for knee hemarthrosis after total knee arthroplasty when conservative therapies have failed and synovial hypervascularity is demonstrated on angiography; splenic artery embolization for hypersplenism secondary to cirrhosis as an alternative to splenectomy; pre-operative embolization of skull base meningiomas; vascular embolization for treatment of type I or type II endovascular leak; renal artery embolization/angioinfarction as a preoperative adjunct to nephrectomy for large hypervascular renal cell carcinoma; selective arterial embolization for giant cell tumor; tumor or pre-operative tumor embolization to reduce intraoperative bleeding for hypervascular tumors or metastases; transcatheter embolization (TACE/TAE) for actively bleeding malignant or nonmalignant lesions; persistent gross hematuria originating from the prostate

See individual items for additional criteria such as localized source identification, hemodynamic instability, transfusion threshold, failed conservative therapy, or angiographic confirmation

Covered Indications with sufficient evidence

Covered when ALL of the following are met for each listed indication

Lower GI bleeding: Super-selective transcatheter embolization is an appropriate primary endovascular treatment for active lower gastrointestinal bleeding, particularly in massive bleeding defined as transfusion requirement of ≥4 units of blood within 24 hoursmassive bleeding defined as transfusion ≥4 units in 24 hours

Feasibility ~98%; complications ~4.6% (most commonly bowel infarction or ulceration)

Portal vein embolization (PVE): Preoperative PVE is indicated when a marginal future liver remnant (FLR) precludes curative hepatectomy in selected patients with primary or metastatic liver tumors to increase resectability; hepatic surgeons generally wait 3–6 weeks post-PVE before resectionApproximately 70–80% of patients undergoing PVE proceed to resection

Documentation should support marginal FLR and planned timing of resection

Prostatic arterial embolization (PAE) for hematuria:

Not medically necessary / Investigational indications

Considered experimental or insufficient evidence when ANY of the following apply

Preventive collateral arteries embolization before EVAR: Preventive embolization of collateral arteries to reduce type II endoleaks, sac enlargement, and re-intervention is promising but evidence is insufficient; higher-quality studies are needed

Meta-analysis included 11 retrospective studies and 1 RCT (1,706 patients)

Locoregional embolization for metastatic pancreatic cancer: Locoregional embolization for metastatic pancreatic ductal adenocarcinoma has insufficient evidence to determine effects on health outcomes; further large, prospective RCTs are needed

Paraumbilical vein coil embolization for hepatic encephalopathy: Evidence is insufficient (very small studies, lack of comparative data)

Endovascular embolization for spinal dural AV fistula (SDAVF):

Coverage by indication (summary)

Coverage stance varies by indication and evidence; when medical criteria are met for specified CPT codes the procedures are considered medically necessary.

Middle Meningeal Artery (MMA) Embolization: Systematic reviews and meta-analyses suggest MMA embolization is associated with lower chronic subdural hematoma recurrence and reduced need for surgical rescue compared with conservative management; however, additional prospective studies are needed to define durability and eligibility criteriaEvidence described as promising but insufficient for definitive outcomes

Further randomized trials required

Pre-operative embolization for Carotid Body Tumor: Pooled data indicate lower intra-operative blood loss and shorter operative duration with pre-operative embolization versus no embolization, but clinical significance of these differences is unclear and evidence insufficient for definitive recommendationsEvidence insufficient for definitive outcomes

Prostatic Arterial Embolization (PAE):

This policy addresses vascular embolization procedures generally but does not address embolization for the liver or uterine fibroids. For those organ-specific interventions, refer to the separate "Prior Authorization via Web-Based Tool for Procedures" policy listed under Related Policies. Because CPT codes for embolization are not region- or indication-specific, a focused medical necessity review is required to determine the exact procedure and condition being treated.

The following procedures and techniques are identified in the policy as having insufficient evidence to determine effects on health outcomes and are considered investigational or needing higher-quality data: preventive collateral artery embolization before EVAR to reduce type II endoleaks; locoregional/embolic treatments for metastatic pancreatic cancer; paraumbilical vein coil embolization for hepatic encephalopathy; endovascular embolization for spinal dural arteriovenous fistula (SDAVF); genicular artery embolization for osteoarthritis-related knee pain; use of HydroPearl microspheres for lower-extremity AVMs; bariatric arterial embolization for obesity; middle meningeal artery (MMA) embolization for chronic subdural hematoma as a definitive therapy; preoperative embolization for carotid body tumor with unclear clinical significance; prostatic arterial embolization (PAE) for BPH (outcomes and long-term benefit uncertain); and catheter-directed hemorrhoidal embolization (preliminary outcomes requiring validation).

This medical policy is provided for informational purposes and is not a guarantee of payment. Member-specific benefits, coverage exclusions, or participation agreements may supersede the policy terms; providers should consult benefit documents or contact the provider call center for plan-specific determinations. If a service is determined not medically necessary (or is a non-covered benefit), providers may not bill the member unless the member has been informed and has given written agreement to accept financial responsibility in advance.

The procedures listed below are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products because evidence is insufficient to determine health outcomes: coil embolization for left ventricular outflow tract (LVOT) pseudoaneurysm; embolization for asymptomatic persistent sciatic artery; locoregional embolization for metastatic pancreatic cancer; endovascular embolization for spinal dural arteriovenous fistula; hemorrhoidal embolization using HydroPearl microspheres; genicular artery embolization for osteoarthritis-related knee pain; HydroPearl microspheres for lower-extremity AVMs; middle meningeal artery embolization for chronic subdural hematoma; bariatric arterial embolization for obesity; paraumbilical vein coil embolization for hepatic encephalopathy; preoperative inferior mesenteric artery embolization to reduce type II endoleak after EVAR; preoperative embolization for carotid body tumor resection; and prostatic arterial embolization for benign prostatic hyperplasia.

Interventions for which the policy specifically notes insufficient evidence include: middle meningeal artery (MMA) embolization for chronic subdural hematoma (promising meta-analytic signals but lacking definitive prospective data); preoperative embolization for carotid body tumor (CBT)—pooled data show reduced intraoperative blood loss and shorter operative time but unclear clinical significance; prostatic arterial embolization (PAE)—single-arm studies and limited randomized data show symptomatic improvements but uncertain long-term benefit and patient selection; and catheter-directed hemorrhoidal embolization—encouraging preliminary outcomes that require validation in well-designed studies.

Coding and Code-Level Thresholds

Covered CPT Codes (examples)CPTCovered

37243

Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to the intervention; for tumors, organ ischemia, or infarction

Covered CPT Codes (examples)CPTCovered

37242

Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)

Renal angiomyolipoma (rAML) size threshold

Renal AML diameter thresholdGreater than 6 cm

Associated indicationEmbolization indicated for renal angiomyolipoma with active bleeding or features associated with higher bleeding risk

Imaging assessmentCT or MRI recommended to assess for hemorrhage when symptoms (flank pain, tenderness, hematuria) present

Transfusion requirement for lower GI bleeding

Transfusion threshold for embolization4 units of blood or more in 24 hours

ContextDefines massive lower GI bleeding and is an indication for transcatheter embolization

Provider Requirements, Prior Authorization, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and is recommended for participating providers on Commercial Products via the web-based tool. Prior authorization expectations apply to supported indications (for example, portal vein embolization prior to hepatic resection and transcatheter embolization for lower GI bleeding) and to indications considered experimental/investigational where review is needed prior to service.

Prior authorization required for Medicare Advantage Plans
Prior authorization recommended for Commercial Products via the web-based tool
See Related Policies: Prior Authorization via Web‑Based Tool for Procedures

Documentation Required

Prior Authorization and Affected Codes

Because the CPT codes used to represent embolization procedures (for example CPT 37242 and 37243) are not specific to a single body region or condition, a medical necessity review is required to determine the specific procedure performed and the clinical indication. Documentation must clearly support the diagnosis and the reason embolization is medically necessary for the member.

Background and Context

Vascular embolization is a minimally invasive endovascular technique used to occlude blood vessels without open surgery. It is employed to stop arterial bleeding, occlude vessels feeding tumors or vascular malformations, reduce intraoperative blood loss for hypervascular lesions, or to redirect blood flow (for example, portal vein embolization to increase future liver remnant). Procedures may use coils, microspheres, glue, or other embolic agents and require angiographic guidance and radiologic supervision.

Definitions and Key Terms

Vascular embolization — definition

DefinitionVascular embolization: procedures that block blood vessels without invasive surgery to stop bleeding, occlude vessels for tumors or malformations, or redirect flow

Common usesStop arterial bleeding, treat tumors, shrink vascular malformations, or redirect blood flow

Policy noteThis policy does not address embolization for the liver or uterine fibroids; refer to separate prior authorization policy

Super-selective embolization — definition/term

DefinitionSuper-selective embolization: catheter-based embolization targeting distal/specific branch vessels (using coaxial/microcatheters) to limit non-target ischemia

Clinical advantage

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyVascular Embolization Procedures — Coverage Criteria

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective Date02 | 01 2026

Next Review DateN/A

Key ActionObtain prior authorization via the web-based tool (required for Medicare Advantage; recommended for Commercial products) and document indication and supporting clinical details.

SourceLink

On This Page

PAE may be reasonable for BPH-induced gross hematuria refractory to medical management for at least 3 months in patients who are not surgical candidates or refuse surgery

medical management failed ≥3 months

Evidence considered sufficient to determine effects on health outcomes for this specific indication

Preoperative tumor embolization: Preoperative embolization to reduce intraoperative bleeding for hypervascular tumors or metastases may be considered medically necessary for selected patientspresence of a hypervascular tumor or metastasis

Used as an adjunct to reduce intraoperative blood loss

Renal artery embolization/angioinfarction as a preoperative adjunct to nephrectomy for hypervascular renal cell carcinoma is acceptable

Considered an acceptable alternative based on available evidence

Meta-analysis suggests higher early failure and long-term recurrence compared with microsurgery and insufficient evidence to establish superiority or equivalent outcomes

Genicular artery embolization for knee osteoarthritis: Evidence is limited to small, low-quality studies; results are promising but further standardized randomized trials are needed

HydroPearl microspheres for lower extremity AVMs: Insufficient evidence to determine effects on health outcomes

Bariatric arterial embolization for obesity: Insufficient evidence; weight loss outcomes less robust compared with bariatric surgery and further study required

Middle meningeal artery (MMA) embolization for chronic subdural hematoma (cSDH): Promising data from meta-analyses showing lower recurrence and surgical rescue rates versus conventional management, but evidence is insufficient for definitive conclusions and further RCTs are needed

Preoperative embolization for carotid body tumor (CBT): Preoperative selective embolization may reduce intraoperative blood loss and operative time, but clinical significance is unclear and evidence insufficient to determine effects on health outcomes

Coil embolization for LVOT pseudoaneurysm and embolization for persistent sciatic artery: Limited literature and case reports; evidence insufficient to determine effects on health outcomes

PAE demonstrates symptomatic improvements and shorter recovery in single-arm studies and limited randomized data, but studies are limited by small sizes and short follow-up; long-term benefit and optimal patient selection remain uncertain

Evidence insufficient for definitive long-term outcomes

Hemorrhoidal Embolization: Catheter-directed hemorrhoidal embolization has encouraging preliminary outcomes for Goligher grade I–III hemorrhoids with bleeding, but requires validation in well-designed studies; evidence is insufficient to determine definitive health outcomesEvidence insufficient

Preferred technique noteSuper-selective transcatheter embolization with microcoils is the primary endovascular treatment for lower GI bleeding

Massive lower gastrointestinal bleeding

Massive lower GI bleeding definitionTransfusion requirement of 4 units of blood or more in 24 hours

Therapeutic implicationMassive bleeding as defined above is an indication for angiographic embolization

Evidence statusEvidence considered sufficient to determine effects on health outcomes for this indication

MMA embolization meta-analysis inclusion

Study inclusion threshold (MMA meta-analysis)Studies reporting outcomes after MMA embolization with ≥ 3 patients were included

Meta-analysis scaleAnalysis comprised 20 studies and 1,416 patients (718 MMA cohort, 698 conventional cohort)

ImplicationInclusion criterion ensured small case series (<3 patients) were excluded from pooled analysis

Affected CPT codes: 37242, 37243
Medical necessity review required to support the specific indication and body region
Documentation should include relevant imaging, prior conservative treatments, hemodynamic status, and transfusion requirements where applicable

Denial Risk

Not Covered / Not Medically Necessary Procedures

Procedures listed in the policy as not covered or not medically necessary for Medicare Advantage and Commercial Products may be denied when billed. Providers should not assume coverage for items listed as investigational or not medically necessary and should obtain prior authorization when in doubt.

Examples of procedures considered not covered / not medically necessary (policy list): genicular artery embolization for osteoarthritis knee pain, prostatic arterial embolization for BPH, hemorrhoidal embolization with HydroPearl, bariatric arterial embolization for obesity, and others as listed in the policy
Services determined to be not covered may result in denial or member financial liability if provided without prior written agreement

Note

Preventive Collateral Embolization Considered Investigational

Preventive collateral artery embolization (for example, embolization of collateral vessels before EVAR to prevent type II endoleak) is considered investigational due to insufficient high‑quality evidence to determine effects on health outcomes.

Preventive collateral embolization before EVAR: investigational / insufficient evidence
High‑quality studies are needed to establish effectiveness for reducing type II endoleaks and reinterventions

Documentation Required

PVE Documentation Needs

For portal vein embolization (PVE) performed to increase future liver remnant (FLR) prior to hepatic resection, documentation must support marginal FLR and the planned timing of subsequent resection (typical surgical waiting period 3–6 weeks post‑PVE). Include imaging, surgical plan, and multidisciplinary rationale in the prior authorization/medical record.

Document marginal FLR measurements and criteria used to determine inadequacy for immediate resection
Provide planned timing for hepatic resection and surgical intent (curative resection)
Include imaging reports, surgical consultation notes, and multidisciplinary planning documentation

Billing Rule

CPT Code Documentation

When CPT codes 37242 and 37243 are used, ensure the submitted documentation supports that medical criteria in this policy are met for the billed indication. Use the most specific code that matches the service provided and include procedure notes, imaging, and evidence of failed conservative therapy when required by the indication.

CPT 37242 and 37243 considered medically necessary only when policy medical criteria are met
Include operative/procedure report, imaging guidance documentation, and indication‑specific supporting records
For indications requiring failure of conservative therapy (e.g., genicular artery embolization for knee hemarthrosis or lower GI bleeding after endoscopic localization and attempts), include documentation of prior therapies and outcomes

Documentation Required

Medical Necessity Review Required

Medical necessity review will determine coverage decisions because CPT codes for embolization are not region‑specific. Providers must supply sufficient documentation to demonstrate that the procedure is being performed for a supported indication; absence of adequate documentation may lead to denial.

Provide indication, prior conservative treatments (when required), imaging localization, hemodynamic/transfusion status, and planned next steps
For supported indications (e.g., transcatheter embolization for massive lower GI bleeding or PVE before resection), include evidence aligning with the policy clinical criteria

Decreases risk of bowel infarction in GI bleeding compared with less selective techniques

Feasibility and complicationsFeasible in ~98% of active lower GI bleeding cases; complications ~4.6% (mostly bowel infarction or ulceration)

Future liver remnant (FLR) and PVE

DefinitionFuture liver remnant (FLR): the portion of the liver that will remain after surgical resection

Relation to PVEPreoperative portal vein embolization (PVE) is used when marginal FLR precludes curative hepatectomy to increase resectability; interval to resection typically 3–6 weeks

Outcome statisticApproximately 70–80% of patients who undergo preoperative PVE eventually undergo successful liver resection

Chronic subdural hematoma (cSDH) — context for MMA embolization

DefinitionChronic subdural hematoma (cSDH): a common neurosurgical condition typically treated with surgical methods (e.g., burr hole irrigation); MMA embolization is a proposed adjunctive or alternative minimally invasive therapy

Evidence contextSystematic reviews/meta-analyses report MMA embolization associated with lower cSDH recurrence and need for surgical rescue versus conventional management, but evidence insufficient for definitive conclusions

Study inclusion detailMeta-analysis included studies reporting outcomes after MMA embolization with ≥3 patients (20 studies, 1,416 patients)

Prostatic arterial embolization (PAE) — definition & context

DefinitionProstatic arterial embolization (PAE): a minimally invasive procedure where an interventional radiologist injects microspheres into prostatic arteries to reduce blood supply to the prostate

Intended effectReduces prostatic blood flow to improve symptoms of benign prostatic hyperplasia (e.g., hematuria) with shorter recovery than TURP

Evidence and limitationsEvaluated in single-arm studies and one randomized trial; studies limited by small sizes and limited long-term outcomes